Perjeta (Pertuzumab) Market 2026–2035 expanding HER2-targeted therapies

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Perjeta (Pertuzumab) Market From 2026 To 2030?

The market for perjeta (pertuzumab) has experienced rapid expansion in recent years. It is projected to expand from $1.08 million in 2025 to $1.26 million in 2026, exhibiting a compound annual growth rate (CAGR) of 15.7%. Historically, this growth was primarily driven by the approval of HER2 monoclonal antibodies, a rising incidence of breast cancer, advancements in HER2 diagnostics, robust clinical trial results, and its inclusion in oncology guidelines.

The Perjeta (pertuzumab) market size is projected to experience swift expansion over the coming years. It is anticipated to reach $2.23 million by 2030, exhibiting a compound annual growth rate (CAGR) of 15.4%. This projected growth throughout the forecast period stems from factors such as enhanced identification of HER2-positive patients, broader application in adjuvant therapy settings, increased adoption of combination regimens, growing expenditure on oncology drugs, and global market penetration. Key trends anticipated during this period encompass the wider availability of HER2-targeted combination therapies, the expanding application in both early and metastatic breast cancer, the increasing acceptance of dual HER2 blockade, a heightened emphasis on precision oncology, and improved survival rates among HER2-positive patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19917&type=smp

What Drivers Are Influencing The Perjeta (Pertuzumab) Market?

The increasing occurrence of breast cancer is anticipated to fuel the expansion of the Perjeta (pertuzumab) market moving ahead. Breast cancer is defined as a condition characterized by the formation of cancerous cells within breast tissue, frequently starting in the ducts or lobules. This rise in breast cancer cases can be linked to evolving lifestyles, such as greater obesity and inactive routines, along with enhanced early identification via extensive screening initiatives. Perjeta (pertuzumab) serves as a treatment for HER2-positive breast cancer, functioning by targeting the HER2 receptor, and is commonly administered alongside trastuzumab and chemotherapy to enhance therapeutic results. For example, data from October 2023, shared by the Ray of Light Wales, a not-for-profit charity based in the UK, indicates that approximately 600,000 individuals are living in the UK following a breast cancer diagnosis, a figure anticipated to reach 1.2 million by 2030. Consequently, the increasing prevalence of breast cancer is stimulating the expansion of the herceptin biosimilars market.

Which Segments Are Included In The Analysis Of The Perjeta (Pertuzumab) Market?

The perjeta (pertuzumab) market covered in this report is segmented –

1) By Source: Human source, Animal source

2) By Product: Monoclonal Antibody, Biologic Drug

3) By Indication: Early Breast Cancer, Metastatic Breast Cancer

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Trends Are Impacting The Growth Of The Perjeta (Pertuzumab) Market?

A primary trend within the Perjeta (pertuzumab) market involves the advancement of technologically sophisticated solutions, particularly subcutaneous combination therapies, aiming to enhance patient results and streamline treatment administration. These therapies describe medical approaches where multiple drugs are delivered together via a single injection beneath the skin to address a specific ailment. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd., a pharmaceutical firm based in Japan, introduced Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This cutting-edge subcutaneous medication brings together the monoclonal antibodies pertuzumab and trastuzumab alongside vorhyaluronidase alfa, enabling administration in a mere 5 to 8 minutes, which substantially cuts down the duration compared to conventional intravenous methods. Phesgo is prescribed for individuals battling advanced or recurrent HER2-positive colorectal cancer, marking it as the first subcutaneous option available for this specific condition.

Which Key Industry Participants Are Active In The Perjeta (Pertuzumab) Market?

Major companies operating in the perjeta (pertuzumab) market are Roche Holding AG

Read the full perjeta (pertuzumab) market report here:

https://www.thebusinessresearchcompany.com/report/perjeta-pertuzumab-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Perjeta (Pertuzumab) Market?

North America was the largest region in the perjeta (pertuzumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Perjeta (Pertuzumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19917&type=smp

Browse Through More Reports Similar to the Global Perjeta (Pertuzumab) Market 2026, By The Business Research Company

Perlite Market Report 2026

https://www.thebusinessresearchcompany.com/report/perlite-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Boat And Ship Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/boat-and-ship-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795